Projects per year
Personal profile
Research Area Keywords
- Neurosciences
- Clinical Translation & Trials
Fingerprint
Dive into the research topics where Sheetal Shroff is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects with Non-Oncology Plasma Cell-Related Diseases
Liao, B. (PI), Ganguly, S. (Key Personnel), Greene, E. P. (Key Personnel) & Shroff, S. (Key Personnel)
5/12/25 → …
Project: Clinical Trial
-
An open-label, multi-center, phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis.
Greene, E. P. (PI), Liao, B. (Key Personnel) & Shroff, S. (Key Personnel)
5/8/25 → …
Project: Clinical Trial
-
An open-label single center, single participant study of an experimental antisense oligonucleotide treatment for amyotrophic lateral sclerosis (ALS) due to TARDBP (TDP-43) genetic mutation
Shroff, S. (PI) & Appel, S. H. (Key Personnel)
3/26/25 → …
Project: Clinical Trial
-
A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants with Amyotrophic Lateral Sclerosis
Shroff, S. (PI)
2/16/24 → 12/31/25
Project: Non Profit
-
MGH Healey Platform Trial Regimen-Specific Appendix F - ABBV-CLS-7262
Shroff, S. (PI)
5/31/23 → 7/23/25
Project: Non Profit
-
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial
Authors/Writing Committee for the HEALEY ALS Platform Trial, Apr 1 2025, In: JAMA: The Journal of the American Medical Association. 333, 13, p. 1138-1149 12 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial
HEALEY ALS Platform Trial Study Group, Feb 3 2025, In: JAMA Network Open. 8, 2, p. e2459058Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study
on behalf of the MG0004 study investigators, Apr 2025, In: Journal of Neurology. 272, 4, 275.Research output: Contribution to journal › Article › peer-review
-
Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial
Writing Committee for the HEALEY ALS Platform Trial, Apr 1 2025, In: JAMA Neurology. 82, 4, p. 333-343 11 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
MG0003 study team, May 2023, In: The Lancet Neurology. 22, 5, p. 383-394 12 p.Research output: Contribution to journal › Article › peer-review
141 Scopus citations